Pan Cancer T B.V., a pioneering biotech firm based in Rotterdam, the Netherlands, has successfully concluded a Seed Extension round, securing €4.25 million. This investment round includes participation from new investor InnovationQuarter, alongside continued support from existing backers such as Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings, bringing Pan Cancer…
Apriori Bio, a pioneering biotechnology firm, has secured a significant funding injection of US $1.1 million from CEPI (Coalition for Epidemic Preparedness Innovations) to propel its cutting-edge artificial intelligence platform, Octavia™. Designed to safeguard against rapidly-evolving viral threats, Octavia™ employs advanced machine learning to predict and counteract virus mutations, crucial for developing variant-resilient vaccines. Octavia™…
Granza Bio Corporation, a trailblazing biotechnology firm rooted in pioneering therapeutic delivery platforms, has successfully concluded an oversubscribed $7.14 million Seed funding round. The funding was led by prominent investors including Felicis and Refactor, alongside participation from Y Combinator and a consortium of esteemed angel investors. Established in 2024 by distinguished researchers from the University…
Zhiyi Biotech, a pioneering clinical-stage biotech specializing in live biotherapeutic products (LBPs), has achieved significant milestones with its latest clinical trial results for SK10. The Phase I study, conducted in the United States, has demonstrated promising outcomes in the treatment of chemotherapy-induced diarrhea (CID) using SK10, an innovative heat-killed Bacteroides fragilis product. The randomized, double-blind,…
A new wave of hope is washing over the oncology field with Myricx Bio’s impressive £90 million ($114 million) Series A funding. This UK biotech company, unlike its peers, isn’t taking an incremental step forward. Instead, they’re wielding a whole new weapon in the fight against cancer: N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugates (ADCs). The significance…
Beacon Therapeutics, a pioneering ophthalmic gene therapy company dedicated to combating blinding retinal diseases, has secured $170 million in Series B funding, marking a significant stride towards advancing its transformative treatments. Led by Forbion and supported by existing investors Syncona and Oxford Science Enterprises, alongside newcomers TCGX and Advent Life Sciences, this funding round will…
Rejuvenate Bio, a pioneering biotechnology firm specializing in gene therapies, announced today the reception of a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to propel the development of its innovative gene therapy, RJB-0402, aimed at treating desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM) is…
Anbogen Therapeutics, a leading name in cancer therapeutics development, has announced the successful completion of an oversubscribed A+ round financing, securing USD 7.3 million to advance their groundbreaking cancer treatment, ABT-301. This latest funding round follows on the heels of a USD 12.5 million Series A round earlier this year, bringing Anbogen’s total funding to…
Kanvas Biosciences, a pioneering spatial biology company, has announced a significant stride in its mission to revolutionize healthcare with microbiome-based therapies. With an additional $12.5 million in funding co-led by DCVC and Lions Capital LLC, and supported by FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures, alongside existing investors, the company’s total funding now…
Waypoint Bio, a pioneering biotechnology firm, has secured $14.5 million in seed funding led by Hummingbird Ventures, alongside Recode Ventures and Fifty Years, to advance its cutting-edge approach in developing cell therapies for solid tumors. Founded by MIT alumni Xinchen Wang and David Phizicky, Waypoint Bio harnesses in vivo spatial pooled screening technology to drive…
